Amplify Weight Loss Drug & Treatment ETF (THNR) holdings & weights
Per-holding contribution · concentration · sector skew — a deep read
Fund overview
This is a US-listed ETF from Amplify Investments. It tracks the VettaFi Weight Loss Drug & Treatment Index. Key facts — expense ratio 0.59%; net assets about $6M; inception May 21, 2024. Its 1-year return is +6.14%.
Fund details
Fund overview
This is a US-listed ETF from Amplify Investments. It tracks the VettaFi Weight Loss Drug & Treatment Index. Key facts — expense ratio 0.59%; net assets about $6M; inception May 21, 2024. Its 1-year return is +6.14%.
13 identified stocks · net exposure / NAV 66.33%. Display weights are normalized to 100%; calculations retain original exposures without an additional leverage multiplier. Cash and unallocated contracts are excluded from stock attribution.
Weight and calculation basis
13 identified stocks · net exposure / NAV 66.33%. Display weights are normalized to 100%; calculations retain original exposures without an additional leverage multiplier. Cash and unallocated contracts are excluded from stock attribution.
We have this ETF's holdings, but the prices for those particular listings are outside our quote coverage (currently Korea- and US-listed securities). So today's contribution and return are not computed — showing 0% would claim it did not move, which is a different statement. The holdings and weights below follow the calculation basis above.
Today's summary
Its top 10 holdings make up about 91.4% of the fund. The concentration index (HHI) is 951 — Low — evenly diversified, and the largest sector is Health Care (97%). The higher the concentration, the more one stock or sector drives the whole ETF's return.
Structural health
A five-axis read on how this fund is built. It is not a return forecast or a recommendation, and a low score does not mean a bad fund — leveraged products score low by design. Each axis shows the figure behind it.
Concentration is below 1,500 (951), so no single holding dominates.
Health Care alone is 97%. This is effectively a bet on that one industry — if the sector falls, diversification will not help.
0.59% a year is on the high side — about 5.9% over a decade, so it needs a reason to earn that.
Net assets of $6M are small. Thin funds trade at wider spreads, and very small ones get closed or merged.
A plain 1x physical fund holding the shares themselves — no structural drift from how long you hold it.
Concentration and diversification
Structural health
A five-axis read on how this fund is built. It is not a return forecast or a recommendation, and a low score does not mean a bad fund — leveraged products score low by design. Each axis shows the figure behind it.
Concentration is below 1,500 (951), so no single holding dominates.
Health Care alone is 97%. This is effectively a bet on that one industry — if the sector falls, diversification will not help.
0.59% a year is on the high side — about 5.9% over a decade, so it needs a reason to earn that.
Net assets of $6M are small. Thin funds trade at wider spreads, and very small ones get closed or merged.
A plain 1x physical fund holding the shares themselves — no structural drift from how long you hold it.
Top 13 holdings
Weights are normalized to 100% of absolute exposures across analysed positions, including positions outside this top list. Cash, collateral and unverified assets are excluded. Contributions retain original signed NAV exposures; leverage is not applied twice.
Normalized to 100% of analysed positions
Weights are normalized to 100% of absolute exposures across analysed positions, including positions outside this top list. Cash, collateral and unverified assets are excluded. Contributions retain original signed NAV exposures; leverage is not applied twice.
| # | Holding | Weight |
|---|---|---|
| 1 | Eli Lilly andLLY | 16.01% |
| 2 | Novo Nordisk A/SNVO | 13.33% |
| 3 | AmgenAMGN | 8.88% |
| 4 | AbbVieABBV | 8.61% |
| 5 | PfizerPFE | 8.44% |
| 6 | Gilead SciencesGILD | 8.17% |
| 7 | MerckMRK | 7.86% |
| 8 | Regeneron PharmaceuticalsREGN | 7.81% |
| 9 | Viking TherapeuticsVKTX | 6.63% |
| 10 | Arrowhead PharmaceuticalsARWR | 5.62% |
| 11 | Structure TherapeuticsGPCR | 3.71% |
| 12 | Jiangsu Hengrui PharmaceuticalsJNGHF | 3.47% |
| 13 | Kailera TherapeuticsKLRA | 1.46% |
Holdings below 0.5% or outside the top list are folded into “Others” and omitted above.
Where the weight sits — sector mix
Listed equity weights summed by sector and normalized to 100%. Each band is one sector's share.
Industry breakdown
HHI sums the squared weights. The more it leans on a few names, the higher it goes — and the more the whole ETF moves with them.
How concentrated is it
Concentration (HHI) is low at 951, with the top 10 holdings at just 91.4% of equity weight. No single name can dominate the fund.
Good for damping single-stock risk — and equally, a big winner inside gets diluted.
HHI squares each weight and sums them: 10,000 means one stock is everything, and the more evenly spread the holdings, the closer it falls to zero.
Where the sector weight sits
By sector, Health Care alone is 97% — whatever the fund is called, this is a bet on that industry.
Bad news for the sector moves the whole fund. Worth checking against anything else you hold in the same space.
Weights above sum the individually listed equities and normalize that equity total to 100%.
How much it overlaps others
It shares 46% of its holdings with OZEM (10 names in common) — close to half the same companies.
Own both and the diversification is thinner than it looks.
What it is made of
The fund holds 23 positions in total; this page lists the largest 13 and folds the rest into "Others".
Equities are 66.3% of the fund, the rest swaps and cash — index exposure built synthetically rather than by owning the shares, which adds counterparty risk.
The expense ratio is 0.59% a year, which is not cheap. Fees come out of returns every year you hold, so it is worth checking whether the same index is available for less.
This page is not investment advice. Investment decisions and responsibility are your own.
THNR comments
Leave a one-line take on Amplify Weight Loss Drug & Treatment ETF. No account — just a nickname and a code to delete it later.
Loading…
Similar ETFs
Picked by how much their actual holdings overlap. The higher the overlap, the less diversification you get from owning both.